KM Research Hub
← 返回论文库
待处理 入排:待复核 图源:待检查 入排置信度 0.45

Trop-2 and Nectin-4 immunohistochemical expression in metastatic colorectal cancer: searching for the right population for drugs' development.

Roberto Moretto, Marco Maria Germani, Mirella Giordano, Veronica Conca, Agnese Proietti, Cristina Niccoli, Filippo Pietrantonio, Sara Lonardi, Emiliano Tamburini, Alberto Zaniboni, Alessandro Passardi, Tiziana Pia Latiano, Valentina Fanotto, Samantha Di Donato, Michele Prisciandaro, Francesca Bergamo, Gianluca Masi, Gabriella Fontanini, Clara Ugolini, Chiara Cremolini

Br J Cancer 128(7) 1391-1399

PMID36759721
PMCIDPMC10049995
DOI10.1038/s41416-023-02180-7
发表日期2023-02-09
入排依据:The record describes a biomarker subgroup analysis of the phase III TRIBE2 randomized trial, reporting OS and PFS outcomes. While it meets the oncology, human, randomized, and phase criteria, and includes relevant survival outcomes, the report is a secondary/subgroup analysis, not the primary or definitive efficacy report of the trial. Eligibility for Kaplan-Meier digitization requires tracing back to the primary trial report, which is not provided here.
摘要

摘要

BACKGROUND: Trop-2 and Nectin-4 are transmembrane proteins overexpressed in many tumours and targets of antibody-drug conjugates (ADC). In metastatic colorectal cancer (mCRC), the role of Trop-2 and Nectin-4 has been poorly investigated. METHODS: Tumour samples of patients randomised in the phase III TRIBE2 were assessed for Trop-2 and Nectin-4 expression. RESULTS: Three hundred eighty-six tumours were assessed for Trop-2 expression. 90 (23%), 115 (30%) and 181 (47%) were Trop-2 high, medium and low, respectively. Patients with low Trop-2 tumours achieved longer PFS (12 versus 9.9 months, p = 0.047) and OS (27.3 versus 21.3 months, p = 0.015) than those with high/medium Trop-2 tumours. These findings were confirmed in multivariate analysis (p = 0.022 and p = 0.023, respectively). A greater OS benefit from treatment intensification with FOLFOXIRI/bevacizumab was observed in patients with high/medium Trop-2 tumours (p-for-interaction = 0.041). Two hundred fifty-one tumours were assessed for Nectin-4 expression. Fourteen (5%), 67 (27%) and 170 (68%) were high, medium and low, respectively. No prognostic impact was observed based on Nectin-4 expression and no interaction effect was reported between Nectin-4 expression groups and treatment arm. CONCLUSIONS: In mCRC, expression levels of Trop-2 and Nectin-4 are heterogeneous, suggesting a target-driven development of anti-Trop2 and anti-Nectin-4 ADCs. Medium/high Trop-2 expression is associated with worse prognosis and higher benefit from chemotherapy intensification.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。